Colorectal cancer claims 200 000 lives in Europe and the USA each year. With 300 000 new cases per year it is the second commonest malignant disease and is therefore highly relevant to general medical practice 1 . What is the place of chemotherapy? As an adjuvant to surgery for Dukes C colon cancer it confers an absolute survival bene®t of about 5%; in colorectal cancer it is largely palliative, improving quality of life and lengthening survival by 6±8 months. For 40 years 5-¯uorouracil (5FU) has been the mainstay. Now mechanistically different drugs such as irenotecan and oxaliplatin are attracting growing interest, and molecular advances are being translated into possible gene therapy and immunotherapy.
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5-FLUOROURACIL
5FU is a prodrug which after intracellular conversion to active metabolites inhibits thymidylate synthase, impairing DNA synthesis largely in the S phase (replication) (Figure 1 ). In addition 5FU metabolites can be falsely incorporated into RNA and DNA, interfering with the normal protein production necessary for cell growth. In advanced colorectal cancer the standard 5FU bolus regimen (an intravenous bolus daily for 5 days every four weeks) produced response rates of 10±15% with a median survival of 8±10 months 2 . This means that 10±15% of patients had at least a 50% reduction in the volume of their disease as de®ned by a product of bidimensional perpendicular measurements on CT or ultrasound scan. In many of these studies a further 25±30% of patients had stabilization of their disease. Both response and stabilization frequently equate with improved quality of life in addition to increased longevity. The toxicity pro®le of this`Mayo regimen' includes nausea and vomiting, diarrhoea, myelosuppression and oral mucositis. With the exception of nausea and vomiting these side-effects arise from the drug's preferential effect on rapidly dividing cells.
Biomodulation of 5-FU
In an effort to modulate the cytotoxic effects of 5FU and so augment ef®cacy, various drugs have been coadministeredÐ for example, methotrexate, levamisole and, to greatest effect, folinic acid (FA).
Folinic acid
When added to 5FU, FA has proved to be clinically synergistic (FA increases thymidylate synthase inhibition, thus depleting cellular thymidine and inducing apoptosis). A meta-analysis indicated that, in advanced colorectal cancer, 5FU/FA combinations gave a response rate of 23% compared with 11% for 5FU alone; a trend towards better overall survival was not statistically signi®cant 2 .
Methotrexate
Methotrexate inhibits dihydrofolate reductase, increasing the formation of 5-¯uorouridine triphosphate, which is incorporated into RNA to induce cell toxicity.
A meta-analysis of eight randomized trials in 1178 patients with advanced colorectal cancer showed a 19% response rate for 5FU plus methotrexate compared with 10% for 5FU alone (median survivals were 10.7 and 9.1 months) 2 Since 5FU has a half life of 8±14 minutes, the argument for infusional therapy is that a higher proportion of susceptible cells will enter the sensitive S-phase than with bolus administration. A meta-analysis of six randomized trials in advanced colorectal cancer showed a response rate of 22% for infusions compared with 14% for bolus therapy, with a small improvement in median survival 3 . The toxicity pro®les differed, with more hand-foot syndrome and less mucositis, diarrhoea and myelosuppression in the infusion group. Since infusional patients require Hickman or percutaneous intravenous central catheter lines, bene®ts in these terms may be offset by factors such as longer inpatient stays and the added risks of infection and thrombosis.
Oral¯uoropyrimidines
Oral¯uoropyrimidines are attracting growing interest. Four multicentre trials in advanced colorectal cancer, comparing oral UFT (uracil/tegafur) plus FA or capacitabine (5FU prodrug) with intravenous 5FU showed about equal ef®cacy and similar median survival. The group receiving oral treatment had more hand-foot syndrome but less mucositis, neutropenia and alopecia. The oral route is more acceptable to patients and will probably be less costly in terms of staf®ng and admission rates 4±7 . This method has also been assessed by two American trials in an adjuvant setting after hepatic metastatectomy, in an attempt to prevent isolated local hepatic recurrence (found in 60% of patients undergoing such resections). The Intergroup trial randomized patients to hepatic metastectomy alone or to surgery plus hepatic artery infusion of FUDR for four cycles and systemic infusion for twelve cycles. Data at 33 months suggest fewer recurrences in the chemotherapy group and a lower 3-year recurrence rate. In the Sloan Kettering trial 156 patients were randomized to either hepatic artery FUDR/dexamethasone plus systemic 5FU/FA or systemic 5FU/FA alone as adjuvant treatment after resection. The early results suggest that the hepatic artery infusion regimen gave 15% greater 2-year survival 9,10 .
NEW APPROACHES

Thymidylate synthase inhibitors
Ralitrexed (tomudex) is a speci®c thymidylate synthase inhibitor that in advanced colorectal cancer (phase III trials) has given response rates similar to those of the Mayo regimen. However, the CRO6 trial indicated that ralitrexed was inferior to the de Gramont regimen (intravenous 5FU) in terms of treatment-related deaths, progression-free survival and quality of life 11 . Despite this disappointing result, there is probably a group for whom ralitrexed will be preferable (e.g. cardiac contraindications to 5FU-based therapy), and this agent is currently being assessed in combination with other cytotoxic agents.
Irinotecan
Irinotecan is a topoisomerase inhibitor that blocks cell division by inducing single-strand DNA breaks. Phase II trials have shown antitumour activity in metastatic colorectal cancer, and even those with 5FU resistance had response rates of 11±23% 12 . In a randomized trial of irinotecan and supportive care versus supportive care alone after 5FU failure, 1-year survival with irinotecan was 36.2% versus 13.8%, and the drug enhanced quality of life and reduced tumour-related symptoms 12 . Common side-effects include an early cholinergic syndrome consisting of bradycardia, diarrhoea, hypotension and abdominal cramps which can be prevented by intravenous or subcutaneous atropine; delayed effects are diarrhoea, neutropenia, vomiting and alopecia.
Preliminary results from a phase III trial in advanced colorectal cancer indicate that response rates and median time to treatment failure are better with irinotecan/FA/ 5FU than with 5FU/FA alone. However, the addition of irinotecan does increase the toxicity 13 
Oxaliplatin
Oxaliplatin is a third-generation platinum analogue which induces DNA cross-linkage and thus apoptotic cell death. Trials have been conducted only in combination with 5FU, since early research indicated synergy and separate toxicity pro®les. The predominant side-effect is peripheral neuropathy which can take two formsÐan acute, sometimes painful, neuropathy exacerbated by cold, also manifesting as laryngeal dysaesthesia; and a chronic cumulative stocking-and-glove peripheral neuropathy. The acute neuropathy can be reversed by stopping or reducing the rate of the infusion; chronic inter-treatment symptoms, related to cumulative dose, may not be fully reversible. Phase II trials in patients with advanced 5FU-resistant colorectal cancer showed a response rate of only 10% with oxaliplatin alone but a response rate of 46% could be obtained with an intensive 5FU/FA/oxaliplatin combination 14 . The timing and coadministration of these agents need clari®cation.
Adjuvant chemotherapy
80% of patients with colorectal cancer undergo surgical resection with the aim of cure, but half of these will develop recurrence as a result of occult micrometastases at the time of surgery. Adjuvant chemotherapy aims to eradicate these cancer cells.
An Intergroup study showed that patients with Dukes stage C colorectal cancer who received surgery/5FU/ levamisole had 33% lower odds of death and 41% less recurrence risk than those treated with surgery alone 15 . Adjuvant therapy in such patients, with 5FU/FA regimens for 6 months, confers an absolute survival bene®t of 5± 6% 16 . In terms of overall survival, 6 months of 5FU/FA adjuvant therapy seems to be as effective as 12 months 1 . In addition, preliminary results of the QUASAR trial suggest that low-dose FA (20 mg/m 2 ) is as ef®cacious as high-dose FA (200 mg/m 2 ) and is better tolerated 17 . Both these ®ndings will substantially reduce the costs of adjuvant therapy. This trial also indicated that levamisole neither delays recurrence nor improves survival.
Trials so far have concentrated on Dukes C colon cancer but the results of studies such as the QUASAR 1 trial for adjuvant treatment of Dukes B colon cancer and stage B/C rectal cancer are awaited. For Dukes B colon cancer patients the case for chemotherapy remains uncertain and patients should continue to be randomized into such trials.
In rectal carcinoma, since local recurrence is more common, radiotherapy is probably more appropriate than systemic chemotherapy; indeed, radiotherapy has been shown to reduce local recurrence and improve absolute survival by about 10% 1 . At present there are no data to suggest added bene®t from adjuvant systemic chemotherapyÐan issue that should be clari®ed by the QUASAR 1 trial. Combined chemotherapy and radiotherapy in the adjuvant setting is associated with more diarrhoea.
Adjuvant infusional therapy via the portal vein
Since micrometastases in the liver (less than 3 mm) derive their blood supply from the portal vein, trials of regional therapy in the adjuvant setting have concentrated on 5FU administration via portal venous infusion (PVI). A metaanalysis of 10 randomized trials showed a 4.7% improvement in absolute survival with PVI compared with surgery alone; however, the con®dence intervals were wide and the statistical bene®t is not robust. Indeed the AXIS trial, the largest single trial of PVI to date, randomizing 4000 patients after surgery to either PVI or observation alone, suggests no signi®cant differences in overall survival 18, 19 . Monoclonal antibodies have been tried as therapeutic agents against solid tumours for 10 years without success. Explanations for the failures include antigenic heterogeneity and poor accessibility of cells in advanced tumours. However, the picture seems more promising in the adjuvant setting. In a randomized trial, a monoclonal antibody, 17±1A, given postoperatively to patients with Dukes C colorectal cancer, seemed to lengthen both overall survival and disease-free survival 20 . Side-effects consisted of mild constitutional and gastrointestinal symptoms. The results of further trials of 17±1A combined with 5FU are awaited. In addition, the antibody is being assessed in the adjuvant setting for Dukes B colon cancers after curative resection.
Gene therapy
Gene therapy encompasses various techniques in which viral vectors are used to insert genes that encode cytokines, tumour suppresser genes and genes which sensitize cells to chemotherapy (such as p53). Phase I trials of virus-directed enzyme prodrug therapy have begun. This technique involves insertion of genes into cells that transcribe enzymes capable of metabolizing prodrugs to potent cytotoxic species. Adenoviral vectors linking the carcinoembryonic antigen (CEA) promoter to the structural gene for the bacterial enzyme cytosine deaminase have been formulated 21 . Cytosine deaminase metabolizes the prodrug 5-¯uorocytosine to 5FU, but transduction of the gene hybrid should only occur in CEA-expressing cells (Figure 2 ). This method should confer tumour selectivity upon the chemotherapeutic agent, allowing 1000-fold higher concentrations of the 5FU in the tumour and neighbouring bystander cells than in the systemic circulation. This method will have to be assessed initially in advanced colorectal cancer and, if found ef®cacious, then tried in the adjuvant setting via the portal vein.
